Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL567061 | 0.91 | MCHR1 (0.59) | MCHR1 | |
| SCHEMBL926849 | 0.91 | MCHR1 (0.70) | MCHR1HTR2C | |
| SCHEMBL926810 | 0.89 | MCHR1 (0.55) | MCHR1HTR2C | |
| SCHEMBL566989 | 0.87 | SMN1; SMN2 (0.63) | MCHR1 | |
| SCHEMBL565918 | 0.87 | SMN1; SMN2 (0.63) | MCHR1 | |
| SCHEMBL565812 | 0.87 | SMN1; SMN2 (0.63) | MCHR1 | |
| SCHEMBL927147 | 0.86 | MCHR1 (0.77) | MCHR1HTR2C | |
| SCHEMBL926789 | 0.86 | MCHR1 (0.77) | MCHR1HTR2C | |
| SCHEMBL928429 | 0.86 | MCHR1 (0.53) | MCHR1 | |
| SCHEMBL928812 | 0.86 | MCHR1 (0.76) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258676-B1 | STABLE VINAMIDINIUM SALT AND NITROGEN-CONTAINING HETEROCYCLIC RING SYNTHESIS USING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2016-02-17 | — | — | EP | disclosed |
| EP-2258676-B1 | STABLE VINAMIDINIUM SALT AND NITROGEN-CONTAINING HETEROCYCLIC RING SYNTHESIS USING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2016-02-17 | — | — | EP | disclosed |
| US-8373007-B2 | Stable vinamidinium salt and nitrogen-containing heterocyclic ring synthesis using the same | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-8373007-B2 | Stable vinamidinium salt and nitrogen-containing heterocyclic ring synthesis using the same | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-8373007-B2 | Stable vinamidinium salt and nitrogen-containing heterocyclic ring synthesis using the same | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-20110015399-A1 | STABLE VINAMIDINIUM SALT AND NITROGEN-CONTAINING HETEROCYCLIC RING SYNTHESIS USING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| US-20110015399-A1 | STABLE VINAMIDINIUM SALT AND NITROGEN-CONTAINING HETEROCYCLIC RING SYNTHESIS USING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| US-20110015399-A1 | STABLE VINAMIDINIUM SALT AND NITROGEN-CONTAINING HETEROCYCLIC RING SYNTHESIS USING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| US-20110015225-A1 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-20 | — | — | US | disclosed |
| US-20110015225-A1 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-20 | — | — | US | disclosed |
| US-20110015225-A1 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-20 | — | — | US | disclosed |
| EP-2261213-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261213-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-12-15 | — | — | EP | disclosed |
| EP-2258676-A1 | STABLE VINAMIDINIUM SALT AND NITROGEN-CONTAINING HETEROCYCLIC RING SYNTHESIS USING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258676-A1 | STABLE VINAMIDINIUM SALT AND NITROGEN-CONTAINING HETEROCYCLIC RING SYNTHESIS USING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2010-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015399-A1 | STABLE VINAMIDINIUM SALT AND NITROGEN-CONTAINING HETEROCYCLIC RING SYNTHESIS USING THE SAME | VRK2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NPM1 | MCHR1 1628/4885HTR2C 1604/4885 |
| US-20110015225-A1 | Heterocyclic compound | MC1R, MCHR1, MCHR2 | MCHR1 2/4885HTR2C 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.